

University of Groningen

## Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Yurista, Salva; Sillje, Herman; Rienstra, Michiel; Boer, de, Rudolf; Westenbrink, Daan

*Published in:*  
 Cardiovascular Diabetology

*DOI:*  
[10.1186/s12933-019-0984-0](https://doi.org/10.1186/s12933-019-0984-0)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
 Publisher's PDF, also known as Version of record

*Publication date:*  
 2020

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Yurista, S., Sillje, H., Rienstra, M., Boer, de, R., & Westenbrink, D. (2020). Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? *Cardiovascular Diabetology*, 19(1), 5. Article 5. <https://doi.org/10.1186/s12933-019-0984-0>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

COMMENTARY

Open Access



# Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer and B. Daan Westenbrink\*

## Abstract

While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly hypertension, may drive AF in the setting of T2DM. But direct mechanisms may also explain this relation, at least in part. In this regard, recent evidence suggests that mitochondrial dysfunction drives structural, electrical and contractile remodelling of atrial tissue in patients T2DM. Mitochondrial dysfunction may therefore be the mechanistic link between T2DM and AF and could also serve as a therapeutic target. An elegant series of experiments published in *Cardiovascular Diabetology* provide compelling new evidence to support this hypothesis. Using a model of high fat diet (HFD) and low-dose streptozotocin (STZ) injection, Shao et al. provide data that demonstrate a direct association between mitochondrial dysfunction and the susceptibility to develop AF. But the authors also demonstrated that the sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, ameliorate electrical and structural remodelling and prevent AF. These findings provide a new horizon in which mitochondrial targeted therapies could serve as a new class of antiarrhythmic drugs.

**Keywords:** Mitochondria, Diabetes, Atrial fibrillation, Sodium-glucose co-transporter-2 inhibitors

## Introduction

Type 2 diabetes mellitus (T2DM) is a major cardiovascular (CV) risk factor, and its global prevalence is predicted to increase from 425 million to 600 million by the year 2045 [1]. The projected number of individuals with atrial fibrillation (AF) in the European Union could reach 14–17 million by 2030 [2]. T2DM and AF have both emerged as cardiometabolic epidemics [1, 2]. Patients with T2D are at a 40% increased risk to develop new-onset AF [3–5] and the risk of new-onset AF increased gradually with advancing diabetic stage [6]. Furthermore, patients with T2D and AF are also at increased risk to for complications of AF such as stroke and systemic embolisms and hospitalisations for heart failure (HF) [7–9]. In

addition, the evidence has suggested that these patients may actually benefit from the use of non-vitamin K oral anticoagulants (NOACs) given the demonstrated efficacy and improved safety profile as compared to warfarin [10]. This improved safety profile was also confirmed in ARISTOTLE trial [11].

The mechanism responsible for the high incidence and increased severity of AF in patients with T2DM is the subject of intense speculation but remains largely enigmatic. Patients with AF and T2DM share common comorbidities such as hypertension, atherosclerosis and obesity [12]. Targeted therapy of risk factors has been shown to improve AF outcomes [13]. An observational cohort study from Korean National Health Insurance Service database suggests avoiding body weight fluctuation, regardless weight gain or weight loss, is important to prevent AF development and to decrease the risk [14, 15].

\*Correspondence: b.d.westenbrink@umcg.nl  
Department of Cardiology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands



Interestingly, an experimental study by Chen et al. showed that insulin resistance promotes interstitial fibrosis and alters calcium handling that induce arrhythmogenesis in the atria [16]. Morphological and functional comparisons of atrial tissue from patients with or without diabetes have revealed that fibrosis was more elevated in diabetic atria [17]. Furthermore, atria from patients with T2DM and AF consistently display evidence for increased oxidative stress, suggesting that the oxidative stress and/or underlying mechanisms may represent a T2DM-specific therapeutic target for AF [18, 19].

The myocardium requires tremendous amounts of energy in the form of adenosine triphosphate (ATP) to sustain its continuous mechanical work [20]. The majority of this energy is generated through oxidative phosphorylation in mitochondria, which comprise about 30% of the myocardial volume. Mitochondrial energy provision is not only essential for contraction and relaxation, but calcium handling by the sarcoplasmic reticulum and ion channel homeostasis are also critically dependent on ATP availability. In addition, mitochondria also important myocellular storage compartments and alterations in mitochondrial calcium handling contribute to arrhythmogenesis, pathological cardiac remodelling, and apoptosis. Mitochondria are also the main cardiac source of reactive oxygen species (ROS), which originate from the electron transport chain during oxidative phosphorylation. Under physiological conditions ROS-induced myocardial damage is minimized through tight control of the mitochondrial redox balance and an efficient and dynamic mitochondrial quality control program. Mitochondrial quality control/mitochondrial dynamics ensure the fitness of the mitochondrial population through continuous quality checks, the elimination of dysfunctional mitochondrial and promoting growth of new organelles [21].

In many patients with heart disease these protective mechanisms fall short, resulting in increases in mitochondrial ROS, reductions in myocardial ATP and the accumulation dysfunctional mitochondria. While mitochondrial dysfunction has been recognised as a therapeutic target in other heart diseases such as heart failure, the role of mitochondrial dysfunction in arrhythmogenesis is not well described. In an elegant study published in *Cardiovascular Diabetology*, Shao et al. confirm and extend upon previous evidence for a mechanistic link between T2DM, mitochondrial dysfunction and AF [22]. In addition, and rendering translational importance, the authors demonstrate that the sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin can reverse mitochondrial dysfunction and ameliorate the susceptibility to develop AF in rats with T2DM. Together, these findings indicate that mitochondrial dysfunction is a potentially

treatable cause of AF, for which therapeutic interventions are already available. In the current commentary we will summarize contemporary evidence for the role of mitochondria in arrhythmogenesis in patients with AF and also discuss the therapeutic perspectives provided by the study by Shao et al. [22].

### **Mitochondrial dysfunction in T2DM and AF**

Mitochondrial dysfunction has been described in many organs of patients with T2DM, including the atria [23]. For instance, mitochondria isolated from the atria of patients with diabetes display reduced mitochondrial respiration and increased oxidative stress, when compared to subjects without diabetes [24]. The mitochondrial architecture and the assembly of the electron transport chain are also altered in patients with T2DM and these ultrastructural changes appear to be even more pronounced in the presence of AF, suggesting a reciprocal relation [25].

Indeed, abnormal mitochondrial structure and function have been reported in animal model of AF [26]. Moreover, the atria of non-diabetic patients with AF already display enhanced mitochondrial DNA damage [27, 28], and reduced respiratory capacity [27, 29]. Mitochondrial dynamics are also altered in patients with AF, characterized by a reduction in mitochondrial biogenesis [30]. Specifically, Jeganathan et al. observed that the main regulator of mitochondrial biogenesis peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 $\alpha$ ) is downregulated in atrial tissue from patients with post-operative AF [30]. Furthermore, molecular markers for mitochondrial volume are also reduced in the atrial tissue from patients with AF [31]. It remains uncertain whether the observed mitochondrial dysfunction is a cause or a consequence of AF.

### **How does mitochondrial dysfunction lead to AF?**

As described above, dysfunctional mitochondria are less able to generate ATP and produce more ROS. Excessive ROS production can disturb cellular electrical activity in two ways. First, ROS has pro-arrhythmic effects by modulating redox-sensitive regulatory domains of multiple proteins involved in excitation contraction coupling, including sarcoendoplasmic reticulum (SR) calcium transport ATPase (SERCA), Na<sup>+</sup> channels, K<sup>+</sup> channels, L-type Ca<sup>2+</sup> channels (LCCs), ryanodine receptors (RyRs), Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX) [32–36]. In addition, ROS can also directly activate signalling such as Ca<sup>2+</sup>/calmodulin dependent kinase II (CaMKII). CaMKII is a multifunctional protein that serves as a nodal regulator of many cellular responses, including excitation–contraction coupling, excitation–metabolism coupling and excitation–transcription coupling [37–40]. CaMKII can be

activated by multiple stimuli, including but not restricted to sustained increases in mitochondrial ROS and hyperglycaemia [37, 41]. The combination of hyperglycaemia and increased ROS which occurs in diabetic atria sets the ideal stage for robust and sustained CaMKII activation, which has been identified as a major driver of arrhythmogenicity in diabetic hearts, and may at least partially explain the high incidence of AF in patients with diabetes [41].

Bioenergetic deficiencies caused by mitochondrial dysfunction may also result in impediments in ion channels homeostasis. [42]. Reductions in ATP levels can lead to the activations of sarcoplasmic ATP-sensitive potassium ( $K_{ATP}$ ) channels, causing shortening of action potential duration (APD) and reduction of action potential amplitude (APA) [43]. Furthermore, reduced mitochondrial ATP production suppresses the activity of SERCA and  $Na^+/K^+$  ATPase, which will alter calcium ( $Ca^{2+}$ ) handling [44, 45] and increase the susceptibility to develop AF [46].

Finally, oxidative stress and bioenergetic deficiencies can also promote cardiomyocyte hypertrophy and interstitial fibrosis, two central drivers of atrial remodelling that promote AF [47]. As described above, atrial remodelling is a hallmark of AF and the degree of atrial remodelling is more pronounced in individuals with diabetes [48]. In summary, mitochondrial dysfunction in atria from diabetic subject can promote AF through multiple mechanisms summarized in Fig. 1. These findings suggest that targeting mitochondria could represent a feasible therapeutic strategy to reduce the burden of AF in diabetic patients.

SGLT2i are designed to reduce hyperglycaemia [49] but have been shown to improve mitochondrial function in ventricular myocardium of diabetic and non-diabetic animal models of heart failure [50, 51]. Dr. Shao et al. tested the hypothesis that these drugs may also preserve mitochondrial function and reduce atrial remodelling in diabetic atria [22]. For this purpose, they employed a combination of high fat diet (HFD) and low-dose streptozotocin (STZ) injection to induce T2DM in male rats. HFD and low-dose of STZ model has been used as a reasonable animal model of T2DM. Similar to pathophysiology in human, this model demonstrates the progression from insulin resistance to hypoinsulinemia and hyperglycaemia [52].

Animals with non-fasting blood glucose levels above 16.7 mmol/l measured 1 week after STZ injection were considered diabetic. Diabetic rats were then randomized to intragastric administration of empagliflozin (10 or 30 mg/kg/day) or vehicle for the duration of 8 weeks. Rats on a normal diet that did not receive HFD or STZ served as controls. After 8 weeks, cardiac structure and


function were measured by echocardiography and a Millar conductance catheter. After sacrifice, atrial tissue was harvested to study histological and molecular indices of atrial remodelling and mitochondrial dynamics. In addition, mitochondria were isolated and their respiratory capacity and membrane potential was probed with the Oroboros system. In separate series of experiments, the hearts were excised and retrogradely perfused using a Langendorff setup to test AF-susceptibility with a well-established burst pacing protocol.

As expected, empagliflozin lowered blood glucose levels and reduced body weight. Moreover, treatment with high dose empagliflozin prevented LA enlargement and reduced cardiomyocyte hypertrophy and interstitial fibrosis. The susceptibility to AF was also normalized to control levels. Empagliflozin reduced oxidative stress as evidenced by increased superoxide dismutase (SOD) activity and reduced malondialdehyde (MDA) concentrations. Furthermore, the reductions in mitochondrial respiration and mitochondrial membrane potential which occurred in diabetic animals were restored to control levels by empagliflozin. Finally, the recovery of mitochondrial function by empagliflozin were accompanied by similar improvements in mitochondrial dynamics.


The study by Shao et al. [22] is worth noticing for several reasons.

First, most studies with SGLT2i have focussed on ventricular myocardium. The current study is the first to show that SGLT2i prevent electrical and structural remodelling of atria and reduces the propensity to develop AF. It was recently shown that SGLT2i can improve outcome in heart failure patients with or without diabetes [53]. Mitochondrial dysfunction and atrial remodelling are relatively independent of the presence of diabetes and similar mito-protective effects have been observed in non-diabetic models. The beneficial effects of SGLT2i could therefore also translate into similar generic benefits patients with AF. Nevertheless, it is also possible that the benefits on the atria occur via changes in plasma metabolites or other indirect effects. Thus, further research is required to confirm this hypothesis.

Second, while several studies have provided suggestive evidence that empagliflozin improves myocardial function, the authors are the first to convincingly show that SGLT2i improve mitochondrial respiration at the organelle level. In addition, the authors are the first to demonstrate that these mito-protective effects also occur in the atrium. In addition, the authors provide evidence that the favourable mitochondrial effects of SGLT2i have the propensity to reduce the burden of AF. Of note, a meta-analysis of 35 studies that included 34,987 T2DM patients showed no difference in AF occurrence between SGLT2i and placebo [54].



**Fig. 1** Contribution of diabetes to pathophysiology of atrial fibrillation. *OXPHOS* oxidative phosphorylation, *ATP* adenosine triphosphate, *ROS* reactive oxygen species, *CaMKII* Ca<sup>2+</sup>/calmodulin dependent kinase II, *AF* atrial fibrillation. Part of illustration elements courtesy of Servier Medical Art



**Fig. 2** Proposed mechanisms for a SGLT2 inhibitors-induced antiarrhythmic effect in diabetes. SGLT2 sodium-glucose co-transporter 2. Part of illustration elements courtesy of Servier Medical Art

## Summary and conclusions

In summary, the present study has extended our knowledge on the effects of SGLT2i and empagliflozin on atrial electrical and structural remodelling in diabetic setting. It provides compelling evidence that mitochondrial dysfunction could serve as a promising therapeutic target in AF, at least in diabetic patients. A proposed mechanism illustrating how SGLT2i could prevent AF in T2DM is shown in Fig. 2. Indeed, further mechanistic studies in both human and animals to better understand the benefits and potential application are warranted. Post-hoc analyses of ongoing and upcoming trials may also help to better define the scope of clinical effects of SGLT2i in patients with prevalent AF and to evaluate their effects on new onset AF. The current analysis provides a first step that may lead to mitochondrial targeted therapy for the treatments of AF in patients with diabetes?

## Abbreviations

T2DM: type 2 diabetes mellitus; AF: atrial fibrillation; HF: heart failure; ATP: adenosine triphosphate; ROS: reactive oxygen species; SGLT2i: sodium-glucose co-transporter 2 inhibitors; PGC-1 $\alpha$ : peroxisome proliferator-activated receptor gamma coactivator 1-alpha; SERCA: sarcoendoplasmic reticulum (SR) calcium transport ATPase; LCCs: L-type Ca<sup>2+</sup> channels; RyRs: ryanodine receptors; NCX: Na<sup>+</sup>/Ca<sup>2+</sup> exchanger; CaMKII: Ca<sup>2+</sup>/calmodulin dependent kinase

II; K<sub>ATP</sub>: ATP-sensitive potassium channels; APD: action potential duration; APA: action potential amplitude; Ca<sup>2+</sup>: calcium; HFD: high fed diet; STZ: streptozotocin; SOD: superoxide dismutase; MDA: malondialdehyde; SGLT2: sodium-glucose co-transporter 2.

## Acknowledgements

Dr. Yurista is supported by a grant from the Indonesia Endowment Fund for Education (LPDP No. 20150722083422). Dr. de Boer is supported by the Netherlands Heart Foundation (CVON DOSIS, Grant 2014-40, CVON SHE-PREDICTS-HF, Grant 2017-21, and CVON RED-CVD, Grant 2017-11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, Grant 917.13.350). Dr. Westenbrink is supported by The Netherlands Organisation for Scientific Research (NWO VENI, Grant 016.176.147).

## Authors' contributions

SRY and BDW wrote the manuscript. All authors revised the article for important intellectual content. All authors read and approved the final manuscript.

## Funding

Not applicable.

## Availability of data and materials

Not applicable.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable. All authors agree to publication, and there are no permissions needed.

**Competing interests**

SRY, HHWS, MR and BDW do not report competing interests relative to this report. The UMCG, which employs Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Roche, Trevena, and ThermoFisher GmbH. Dr. de Boer received personal fees from MandalMed Inc, Novartis, and Servier.

Received: 22 October 2019 Accepted: 26 December 2019

Published online: 07 January 2020

**References**

- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2019. <https://doi.org/10.1093/eurheartj/ehz486>.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–962.
- Benjamin EJ. Independent risk factors for atrial fibrillation in a population-based cohort. *JAMA*. 1994;271:840.
- Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. *Am J Med*. 1995;98:476–84.
- Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol*. 2011;108:56–62.
- Kim YG, Han K-D, Choi J-I, Boo KY, Kim DY, Oh S-K, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. *Cardiovasc Diabetol*. 2019;18:128.
- Laupacis A. The Efficacy of aspirin in patients With atrial fibrillation. *Arch Intern Med*. 1997;157:1237.
- Karayiannides S, Lundman P, Friberg L, Norhammar A. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: a nationwide report. *Diab Vasc Dis Res*. 2018;15:31–8.
- Laupacis A. Risk-factors for stroke and efficacy of antithrombotic therapy in atrial-fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994;154:1449–57.
- Yamagishi S. Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. *Cardiovasc Diabetol*. 2019;18:12.
- Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *Am Heart J*. 2017;185:140–9.
- Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? *J Cardiovasc Dis Res*. 2010;1:9–11.
- Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk factor management in atrial fibrillation. *Arrhythmia Electrophysiol Rev*. 2018;7:118.
- Lee H-J, Choi E-K, Han K-D, Lee E, Moon I, Lee S-R, et al. Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. *Hear Rhythm*. 2019. <https://doi.org/10.1016/j.hrthm.2019.09.029>.
- Gallagher C, Stokes MB, Sanders P, Lau DH. Bodyweight fluctuation and atrial fibrillation: a new risk factor? *Hear Rhythm*. 2019. <https://doi.org/10.1016/j.hrthm.2019.10.023>.
- Chan Y-H, Chang G-J, Lai Y-J, Chen W-J, Chang S-H, Hung L-M, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. *Cardiovasc Diabetol*. 2019;18:125.
- Lamberts RR, Lingam SJ, Wang H-Y, Bollen IAE, Hughes G, Galvin IF, et al. Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. *Cardiovasc Diabetol*. 2014;13:72.
- Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. *J Cardiovasc Pharmacol*. 2008;52:306–13.
- Gutierrez A, Van Wagoner DR. oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation. *J Cardiovasc Pharmacol*. 2015;66:523–9.
- Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, et al. Assessing cardiac metabolism. *Circ Res*. 2016;118:1659–701.
- Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Mitochondrial function as a therapeutic target in heart failure. *Nat Rev Cardiol*. 2017;14:238–50.
- Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. *Cardiovasc Diabetol*. 2019;18:165.
- Yaribeygi H, Atkin SL, Sahebkar A. Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function. *J Cell Physiol*. 2019;234:8402–10.
- Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neuffer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. *J Am Coll Cardiol*. 2009;54:1891–8.
- Kanaan GN, Patten DA, Redpath CJ, Harper M-E. Atrial fibrillation is associated with impaired atrial mitochondrial energetics and supercomplex formation in adults With type 2 diabetes. *Can J Diab*. 2019;43(67–75):e1.
- Ausma J, Wjffels M, Thoné F, Wouters L, Allesie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. *Circulation*. 1997;96:3157–63.
- Lin P-H, Lee S-H, Su C-P, Wei Y-H. Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. *Free Radic Biol Med*. 2003;35:1310–8.
- Tsuboi M, Hisatome I, Morisaki T, Tanaka M, Tomikura Y, Takeda S, et al. Mitochondrial DNA deletion associated with the reduction of adenine nucleotides in human atrium and atrial fibrillation. *Eur J Clin Invest*. 2001;31:489–96.
- Ad N, Schneider A, Khaliulin I, Borman JB, Schwalb H. Impaired mitochondrial response to simulated ischemic injury as a predictor of the development of atrial fibrillation after cardiac surgery: in vitro study in human myocardium. *J Thorac Cardiovasc Surg*. 2005;129:41–5.
- Jeganathan J, Saraf R, Mahmood F, Pal A, Bhasin MK, Huang T, et al. Mitochondrial dysfunction in atrial tissue of patients developing postoperative atrial fibrillation. *Ann Thorac Surg*. 2017;104:1547–55.
- Tu T, Zhou S, Liu Z, Li X, Liu Q. Quantitative proteomics of changes in energy metabolism-related proteins in atrial tissue from valvular disease patients with permanent atrial fibrillation. *Circ J*. 2014;78:993–1001.
- Priest BT, McDermott JS. Cardiac ion channels. *Channels*. 2015;9:352–9.
- Maack C, O'Rourke B. Excitation-contraction coupling and mitochondrial energetics. *Basic Res Cardiol*. 2007;102:369–92.
- Murphy E, Eisner DA. Regulation of intracellular and mitochondrial sodium in health and disease. *Circ Res*. 2009;104:292–303.
- Williams GSB, Boyman L, Chikando AC, Khairallah RJ, Lederer WJ. Mitochondrial calcium uptake. *Proc Natl Acad Sci USA*. 2013. <https://doi.org/10.1073/pnas.1300410110>.
- Zhou L, Aon MA, Liu T, O'Rourke B. Dynamic modulation of Ca<sup>2+</sup> sparks by mitochondrial oscillations in isolated guinea pig cardiomyocytes under oxidative stress. *J Mol Cell Cardiol*. 2011;51:632–9.
- Joiner MA, Koval OM, Li J, He BJ, Allamargot C, Gao Z, et al. CaMKII determines mitochondrial stress responses in heart. *Nature*. 2012;491:269–73.
- Blaich A, Welling A, Fischer S, Wegener JW, Kostner K, Hofmann F, et al. Facilitation of murine cardiac L-type Cav1.2 channel is modulated by calmodulin kinase II-dependent phosphorylation of S1512 and S1570. *Proc Natl Acad Sci*. 2010;107:10285–9.
- Ho H-T, Liu B, Snyder JS, Lou Q, Brundage EA, Velez-Cortes F, et al. Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides. *Cardiovasc Res*. 2014;101:165–74.
- Westenbrink BD, Edwards AG, McCulloch AD, Brown JH. The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. *Expert Opin Ther Targets*. 2013;17:889–903.
- Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. *Nature*. 2013;502:372–6.
- Overend CL, Eisner DA, O'Neill SC. Altered cardiac sarcoplasmic reticulum function of intact myocytes of rat ventricle during metabolic inhibition. *Circ Res*. 2001;88:181–7.
- Zhou L, Cortassa S, Wei A-C, Aon MA, Winslow RL, O'Rourke B. Modeling cardiac action potential shortening driven by oxidative stress-induced

- mitochondrial oscillations in guinea pig cardiomyocytes. *Biophys J*. 2009;97:1843–52.
44. Ziegelhöffer A, Kjeldsen K, Bundgaard H, Breier A, Vrbjar N, Dzurba A. Na, K-ATPase in the myocardium: molecular principles, functional and clinical aspects. *Gen Physiol Biophys*. 2000;19:9–47.
  45. De Marchi U, Castelbou C, Demaurex N. Uncoupling protein 3 (UCP3) modulates the activity of sarco/endoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase (SERCA) by decreasing mitochondrial ATP production. *J Biol Chem*. 2011;286:32533–41.
  46. Heijman J, Voigt N, Nattel S, Dobrev D. Calcium handling and atrial fibrillation. *Wien Med Wochenschr*. 2012;162:287–91.
  47. Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. *Cardiovasc Diabetol*. 2017;16:120.
  48. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. *Diabetes Obes Metab*. 2019;21:210–7.
  49. de Leeuw AE, de Boer RA. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. *Eur Heart J Cardiovasc Pharmacother*. 2016;2:244–55.
  50. Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten E, Pavez Giani MG, Hillebrands J, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. *Eur J Heart Fail*. 2019;21:862–73.
  51. Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. *Physiol Rep*. 2018;6:e13741.
  52. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. *J Diabetes Investig*. 2014;5:349–58.
  53. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019. <https://doi.org/10.1056/NEJMoa1911303>.
  54. Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2018;25:495–502.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

